Results 221 to 230 of about 135,947 (293)

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

open access: yesCancer, Volume 132, Issue 10, 15 May 2026.
Momelotinib demonstrated robust real‐world activity after ruxolitinib failure, with clinically meaningful improvements in spleen (≥50% spleen length reduction, 30.0%), symptoms (≥50% total symptoms score reduction, 39.2%), and anemia (major response, 35.7%) at 6 months.
Francesca Palandri   +41 more
wiley   +1 more source

The Beginnings of Bronchitis [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1969
openaire   +2 more sources

Poster Sessions

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Publication Only

open access: yes
HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Home - About - Disclaimer - Privacy